Isolation of a novel lytic bacteriophage against a nosocomial methicillin-resistant Staphylococcus aureus belonging to ST45 by Pertics, Botond Zsombor et al.
Research Article
Isolation of a Novel Lytic Bacteriophage against a Nosocomial
Methicillin-Resistant Staphylococcus aureus Belonging to ST45
Botond Zsombor Pertics ,1 Dalma Szénásy,1 Dániel Dunai,1 Yannick Born,2 Lars Fieseler,2
Tamás Kovács,3 and György Schneider 1
1Department of Medical Microbiology and Immunology, Medical School, University of Pécs, Szigeti st. 12., H-7624 Pécs, Hungary
2Institute of Food and Beverage Innovation, Food Microbiology, ZHAW School of Life Sciences and Facility Management,
Einsiedlerstrasse 31, 8820 Wädenswil, Switzerland
3Department of Biotechnology, Nanophagetherapy Center, Enviroinvest Corporation, Kertváros u. 2., H-7632 Pécs, Hungary
Correspondence should be addressed to György Schneider; schneider.gyorgy@pte.hu
Received 14 July 2020; Revised 19 November 2020; Accepted 9 December 2020; Published 23 December 2020
Academic Editor: Mohamed Salah Abbassi
Copyright © 2020 Botond Zsombor Pertics et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Methicillin-resistant Staphylococcus aureus (MRSA) can cause a wide range of infections from mild to life-threatening conditions.
Its enhanced antibiotic resistance often leads to therapeutic failures and therefore alternative eradication methods must be
considered. Potential candidates to control MRSA infections are bacteriophages and their lytic enzymes, lysins. In this study, we
isolated a bacteriophage against a nosocomial MRSA strain belonging to the ST45 epidemiologic group. The phage belonging to
Caudovirales, Siphoviridae, showed a narrow host range and stable lytic activity without the emergence of resistant MRSA
clones. Phylogenetic analysis showed that the newly isolated Staphylococcus phage R4 belongs to the Triavirus genus in
Siphoviridae family. Genetic analysis of the 45 kb sequence of R4 revealed 69 ORFs. No remnants of mobile genetic elements
and traces of truncated genes were observed. We have localized the lysin (N-acetylmuramoyl-L-alanine amidase) gene of the
new phage that was amplified, cloned, expressed, and purified. Its activity was verified by zymogram analysis. Our findings
could potentially be used to develop specific anti-MRSA bacteriophage- and phage lysin-based therapeutic strategies against
major clonal lineages and serotypes.
1. Introduction
Staphylococcus aureus is considered one of the most impor-
tant pathogens, responsible for nosocomial infections affect-
ing skin, respiratory system, bone, and soft tissues. These
infections are frequently a challenging threat, due to the prev-
alent occurrence of antibiotic multidrug resistance among the
isolates [1]. Methicillin-resistant S. aureus (MRSA) shows
high risk to develop resistance to all available antibiotics in
the near future [2].
Isolates have been categorized into three major groups,
according to clinical and molecular epidemiology: (1)
healthcare-associated (HA), (2) community-associated (CA),
and (3) livestock-associated (LA)MRSAs. Distinction between
these groups has become blurry because onset and subsequent
infection routes can vary [3].
Multilocus sequence typing (MLST) is a widely accepted
method for studying the origin, evolution, and clonal popula-
tion structure of MRSA isolates [4]. With this method, several
sequence types (ST) can be differentiated, including ST1, ST5,
ST8, ST22, ST30, ST80, and ST239 which are the most fre-
quently isolated global clones [5]. An emerging ST type is
ST45, the closest relative of ST5 and ST22, and a major inter-
national representative of the epidemic MRSA (EMRSA)
group [4]. ST45 was reported to be one predominant sequence
type of HA-MRSAs and CA-MRSAs in Europe [6–9], North
America [10, 11], Asia [12–16], and Australia [17]. This
sequence type was associated with multiple serious infections
[10, 18] and multiresistance to antibiotic therapy [10].
As antibiotic resistance is growing among the isolates,
novel methods have to be seriously considered as potential
therapeutic or preventive agents.
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Bacteriophages (phages) are bacterial viruses that are able
to kill the target bacterium cell. Unique features of bacterio-
phages allow them to recognize specific receptor structures
on the surface of the bacterium cells, dock, and infect the host
cell subsequently releasing phage progenies [19].
All known phages that infect S. aureus are the members of
the Caudovirales order [20] and produce lysins, a group of
evolutionarily advanced muralytic lytic enzymes that hydro-
lyze the bacterial cell wall peptidoglycan of bacteria [21, 22].
Application of bacteriophages against S. aureus has been
implemented successfully in different models and in medi-
cine. Their in vivo antibacterial effects and, by this, their rai-
son d’etre in therapy were demonstrated in some recent
studies [19, 23–26]. The ability of bacteria to develop resis-
tance against certain phages [27], however, raises the need
for prudent therapeutic approaches. Aside from the applica-
tion of the ideal broad host range phages of S. aureus, narrow
range phages must also be considered for full therapeutic
coverage [28–31]. This could potentially eliminate the
appearance of bacterial resistance and may increase the
immediate antimicrobial effect, as theoretically more phage
receptor types could be engaged by the different phages on
the complex cell envelope structure of S. aureus [32, 33].
Using a library of multitudinous Staphylococcal phages with
different receptor specificities enables us to target a broader
range of bacterial strains, and with the help of narrow host
range phages, a therapeutic broad host range effect can be
gained. Thus, making phage libraries is an important strategy
in the development of phage-based therapy.
Recombinant lytic phage enzymes such as endolysins or
virion-associated lysins (VALs) are potential candidates for
therapy, decolonization, and by this, infection prevention
[34–36]. Lysins bind to and cleave highly conserved struc-
tures in the peptidoglycan layer that are highly immutable;
thus, resistance against them is a rare event [21]. Therefore,
recombinant endolysins are antimicrobial agents [37] with
a high potential to treat Gram-positive bacterial infections
such as MRSA [38, 39].
In this study, we isolated a novel lytic bacteriophage (R4),
which was effective against a resident HA-MRSA isolate,
originating from a German hospital and belonging to the
international ST45 clonal group with growing epidemiologi-
cal potential. We have identified, cloned, and expressed its
cell wall degrading endolysin (amidase). Our results may
aid the development of anti-MRSA bacteriophage-based
therapeutic strategies targeting major clonal lineages.
2. Materials and Methods
2.1. Bacterial Strains and Growth Conditions. The clinical
methicillin-resistant Staphylococcus aureus (MRSA) isolate
06-01019 (ST45) was isolated from the nostril of a hospitalized
patient on selective mannitol salt agar. Species confirmation
was performed by using Matrix-Assisted Laser Desorption/
Ionization–Time of Flight Mass Spectrometry (MALDI-
TOF MS) (Vitek MS, Biomerieux, Marcy-l’Étoile, France).
The bacterium was routinely grown on lysogeny broth (LB)
agar plates at 37°C or liquid LB medium (37°C at 125 rpm).
To create a bacterial lawn, 100μl of the overnight (ON) liquid
culture was plated onto a solid LB agar plate and incubated
ON at 37°C. For amplification of bacteria and/or phages,
ON cultures were poured into larger amounts of liquid
medium and were incubated at 37°C in an orbital shaker.
2.2. Phage Isolation, Propagation, and Titer Determination.
Bacteriophages were isolated from the local sewage farm
(Pellérd, Hungary) with the traditional method [40]. Briefly,
1ml of sewage sample was coincubated with the 50ml midlog
suspension of isolate 06-01019 ON at 37°C. The suspension
was centrifuged (4,000 rpm, 10min), and the supernatant
was treated with chloroform in 1 : 50 v/v ratio (Molar Chemi-
cals Kft., Halásztelek, Hungary) ON at 4°C. The presence of
lytic phages was confirmed by spot testing [40] on the lawn
of isolate 06-01019. A single phage plaque was cut out by
using the agar overlay method [41] and was purified in three
consecutive steps. The purified phage clone, named “Staphy-
lococcus phage R4” according to the recent phage nomencla-
ture [42], was propagated in 100ml LB medium, centrifuged
(11,000 rpm, 30min), and resuspended in 50ml deionized
water (DW). The phage titer was obtained by serially diluting
the phage suspension and subsequently spotting 10microliters
from the dilutions to get a countable amount of individual pla-
ques on the lawn. Then, the number of plaque-forming units
(PFU) was calculated for 1ml of the concentrated suspension.
The resulting high titer suspension (109 PFU/ml) was used for
further studies.
2.3. Host Range Determination and Phage Resistance
Detection. Host range of R4 phage was determined by spot
testing on 42MRSA and 3 S. aureus strains from different col-
lections. From the MRSAs, 14 HA-MRSA and CA-MRSA
possessed known sequence types, as listed in Table 1. A clear
spot indicated that the phage can kill the bacteria. Three dis-
tinct possible values were defined in terms of lytic efficacy,
according to the clarity of the spot: fully cleared, partially
cleared, and no clearance. Results were gathered as the mean
of three different observations. The emergence of resistant
mutants against R4 was tested on the lawn (2 × 108/100μl)
of the clinical methicillin-resistant Staphylococcus aureus
(MRSA) isolate 06-01019 (ST45), by dropping 10μl dense
phage suspension (109 PFU/ml) on it and let it dry. This
phage-covered area contained 107 PFUs of R4 and around
3:5 × 106 bacteria. After 24 hours of incubation, lack or emer-
gence of phage resistant clones was visually detected.
2.4. Transmission Electron Microscopy (TEM). Morphology
of R4 phage was performed by TEM as described recently
[43]. Briefly, 10μl from the purified high titer (109 PFU/ml)
phage stock was deposited onto formvar-coated copper grids
(Pelco Grids, Redding, Canada) and negatively stained with
1.5% w/v phospho-tungstic acid (Merck KGaA, Darmstadt,
Germany) for 40 seconds. After drying, phages were visual-
ized on a JEM-1400 Flash TEM (JEOL USA Inc., Peabody,
USA) transmission electron microscope operated at 80 kV
acceleration voltage, with 54μA beam current.
2.5. Phage Genome Sequence Determination and Bioinformatic
Analysis. Phage DNA was isolated from phage stocks with a
concentration ≥109 PFU/ml. Phage DNA was extracted and
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purified based on the recently described method [43]. A phage
lysate from the high titer phage suspension was obtained by
using a QIAGEN LambdaMidi Kit (QIAGEN Inc., California,
USA) and following the manufacturer’s protocol. The purified
phage DNA was dissolved in 100μl of sterile nuclease-free
H2O and was used to prepare Genomic DNA sequencing
libraries by using the Nextera XT Library Preparation kit (Illu-
mina, California, USA). Sequencing was performed using
MiSeq Reagent Kit v2 (2 × 150 bp) on an Illumina MiSeq
instrument (Illumina, California, USA). The Mypro pipeline
was used to assemble the gained pure sequences.
The assembled sequence was annotated on the RAST
server (https://rast.theseed.org/FIG/rast.cgi). CLC Sequence
Viewer v.6 (CLC bio, Aarhus, Denmark) was used to analyze
the annotated genome and to illustrate the genome map.
Open reading frames (ORFs) and gene predictions were con-
firmed by GeneMarkS program [44]. Homology searches
were conducted by the BLAST tools available at NCBI web-
site (https://www.ncbi.nlm.nih.gov/blast). R4 phage was clas-
sified according to the guidelines of the International
Committee on Taxonomy of Viruses (ICTV, http://talk
.ictvonline.org/taxonomy/) supported by ViralZone (http://
viralzone.expasy.org) and BLASTn results. Protein homology
prediction was conducted by NCBI BLASTp and HHpred
tool of MPI Bioinformatics Toolkit (http://toolkit.tuebingen
.mpg.de/tools/hhpred).
The nucleotide sequence of R4 was deposited in the Gen-
Bank database under the accession number MT366568.
2.6. Phylogenetic Analysis of R4 Phage.Whole genome-based
phylogenetic analysis was conducted with VICTOR [45],
involving the first 27 highly similar siphophages, according
to the homology searches. All pairwise comparisons of the
nucleotide sequence were conducted using the Genome-
BLAST Distance Phylogeny (GBDP) method, under settings
recommended for prokaryotic viruses. Branch support was
inferred from 100 pseudobootstrap replicates each. Tree
was rooted at the midpoint [46] and visualized with FigTree
[47]. Taxon boundaries at the species, genus, and family level
were estimated with the OPTSIL program, with the
Table 1: Host range of the R4 phage. Bold and italic fonts indicate the full and partial lysis of the strain by R4, respectively. Host strain of
phage R4 is marked with an asterisk.
Species Strain code/origin Sequence type R4 phage effect
HA-MRSA
06-01388 ST247 No lysis
93-01000 ST254 Full lysis
06-01597 ST239 No lysis
06-02182 ST22 No lysis
06-01019 ST45 Full lysis∗
06-01750 ST228 No lysis
06-00219 ST5 No lysis
06-00409 ST225 No lysis
CA-MRSA
03-02773 ST1 Full lysis
06-00631 ST5 Partial lysis
06-00373 ST8 Partial lysis
05-01089 ST22 Partial lysis
06-02000 ST80 No lysis
06-00467 ST152 No lysis
MRSA
South Transdanubian Regional
Public Health Institute, Hungary (19 strains)
Full lysis (8 strains)











OEK 112016 No lysis
OEK 112017 No lysis
ATCC 29213 No lysis
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recommended clustering thresholds and an F value (fraction
of links required for cluster fusion) of 0.5 [48].
2.7. Cloning of the Endolysin Gene. The designed primer pairs




ACT-3′ (Sigma-Aldrich, St. Louis, USA)) were used to
amplify orf27, coding for an endolysin (amidase) from the
purified DNA of R4 phage. The PCR reaction was performed
by using the Pfu DNA polymerase enzyme mix (Thermo
Fisher Scientific, Waltham, USA) with the following condi-
tions: denaturation at 95°C for 2 min, followed by 30 cycles,
consisting of 95°C and 30 seconds denaturation, 54°C and
30 seconds annealing, and 72°C and 1 min elongation. The
amplification was ended by an additional 10 min 72°C post-
elongation phase. The amplified PCR fragment was separated
(1% agarose gel), extracted (Gel Extraction Kit; Thermo
Fisher Scientific, Waltham, USA), and blunt-end cloned
(ON, 20°C) into the linearized pJET1.2/blunt plasmid by
using the Clone JET PCR Cloning Kit (Thermo Fisher Scien-
tific, Waltham, USA). The ligation mixture was heat-shock
transformed into the laboratory Escherichia coli strain XL1-
Blue. The integrated PCR insert was double digested with
XhoI and HindIII (Thermo Fisher Scientific, Waltham,
USA), and after separation (1% agarose gel) and the consec-
utive purification (Gel Extraction Kit) step, it was religated
into the XhoI and HindIII linearized pRSET A expression
vector (Thermo Fisher Scientific, Waltham, USA). Ligated
constructs were ethanol precipitated and, after resuspension
in DW, were electroporated into the laboratory E. coli strains
DH5α and BL21 by using 1mm diameter cuvettes and the
GenePulser XCell system (Bio-Rad, Hercules, USA) with
1.8 kV voltage and 600Ω resistance. Transformed cells were
selected on ampicillin-containing (100μg/ml) LB agar plates
incubated ON at 37°C. Integration and presence of the result-
ing orf27-pRSET A construct was confirmed with the double
digestion of the isolated plasmids and with PCR.
2.8. Protein Expression, 1 Dimensional Gel-Electrophoresis.
5ml ON cultures of (1) BL21, (2) BL21 with pRSET A, and
(3) BL21 containing the orf27-pRSET A plasmid construct
were used to start log phase (OD600=0.8) cultures and were
further incubated without (control) and with isopropyl-β-
D-thiogalactoside (IPTG) reaching 2 mM final concentra-
tion. From the resulting cultures, 1ml samples were taken
at 0, 1, 2, 3, 4, and 5 h timepoints. Samples were centrifuged,
and the pellets were resuspended either in distilled water
boiling at 100°C for 10 min, or in sonication buffer (pH 7.4,
50 mM Tris, 1 mM EDTA) for sonication. Sonication was
performed four cycles of 0.5-0.5 seconds of pulsation for 1
min at 25-30% amplitude. After each cycle, there was a 1-2
min incubation period on ice. Boiled or sonicated samples
were mixed with 1 : 4 (v/v) volume of 5x Sample Buffer (0.6
ml 1 M Tris pH 6.8, 5 ml 50% glycerol, 2 ml 10% sodium
dodecyl sulfate (SDS), 0.5 ml β-mercaptoethanol, bromophe-
nol blue, filled with distilled water up to 10 ml) and electro-
phoresed on a 10% polyacrylamide gel [49] for 1.5 h at 120
V, using the Bio-Rad Mini Protean II system (Bio-Rad, Her-
cules, USA). After separation, bands were visualized with
Coomassie Brillant Blue (R-250, Reanal, Budapest, Hungary)
staining [50].
Polyhistidine tag-based affinity purification of the
expressed endolysin was performed from 10ml log phase cul-
ture that was induced with IPTG (2 mM) for 5 h. The centri-
fuged pellet was resuspended in His-binding buffer and was
sonicated as described above. Purification of the endolysin
was implemented with the His-Spin ProteinMiniprep (Zymo
Research, Irvine, USA), according to the protocol. The puri-
fied protein was also visualized by polyacrylamide gel
electrophoresis.
2.9. Zymography. Zymography analysis was carried out as
previously described with modifications [51]. Briefly, S.
aureus isolate 06-01019 (ST45) was grown and collected
from 200 ml of log phase culture. After washing the pellet
with 25 ml lysis buffer A (pH 6.2, 50 mM ammonium acetate,
10 mM CaCl2, 1 mM dithiothreitol), the pellet was resus-
pended in 1.5 ml lysis buffer A. Of this, 500μl was added to
3 ml lysis buffer A, resulting in a solution of OD600=~10.
From this dense bacterial suspension, 500 μl was incorpo-
rated into 5 ml total volume of 10% polyacrylamide separat-
ing gel (1.665 ml acrylamide/bis-acrylamide, 1.25 ml 1.5 M
Tris (pH 8.8), 5 μl 10% SDS, 1.7 ml distilled water, 35μl
10% ammonium persulfate and 2.5 μl TEMED), which was
casted subsequently. Sonicated and purified samples were
electrophoresed (120 V, 1.5 h). The gel was then washed with
DW for 30 min, and with renaturation buffer (pH 6.9, 25 mM
Tris-HCl, 10 mM MgCl2, 0.1% Triton X-100) at 37
°C ON.
The gel was stained for 3 h in 0.1% methylene blue contain-
ing 0.01% KOH and destained with DW until the cleared
zones were visible.
3. Results
3.1. Morphological Features of R4 Phage. R4 is a tailed phage
with an approximately 100 nm long and 50 nm wide prolate
head. The flexible tail is about 300 nm long (Figure 1). This
morphology is a characteristic of the members of the Tria-
virus genus, Siphoviridae family. The phage produces rela-
tively small individual plaques with a diameter of 0.5mm
on the host strain lawn after overnight incubation at 37°C.
3.2. Host Spectrum of R4 Phage and Phage Resistance Testing.
The results of host spectrum determination can be seen in
Table 1. Out of 45 examined strains (including the host), 14
seemed to be susceptible on different levels to the R4 phage,
and 31 were totally resistant. Besides its host strain (06-
01019), phage R4 showed a strong lytic effect on one HA-
MRSA strain (ST254) and one CA-MRSA (ST1) (Table 1).
A partial lytic effect was revealed against three CA-MRSA
strains (ST5, ST8, and ST22). Out of 19 more tested MRSA
isolates from another collection, 8 were susceptible and
showed full lysis, while 11 were resistant. The remaining 9
MRSA and the 3 S. aureus from different collections showed
no sensitivity to the R4 phage.
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No emergence of resistant clones was detected during the
study on the lawn of the clinical methicillin-resistant Staphy-
lococcus aureus (MRSA) isolate 06-01019 (ST45).
3.3. Genomic Properties of R4 Phage. Basic genome statistics
revealed that R4 phage has a 27.902MDa double-stranded,
linear DNA with a length of 45 168 base-pairs and a G+C
content of 33.3% (37.4% adenine, 13.7% cytosine, 19.6% gua-
nine, 29.3% thymine).
The genome shows homology with Staphylococcus phage
SAP8 (MK801680.1), SMSAP5 (JQ779023.1), SH-St 15644
(MG770897.1), and vB_SauS_fPfSau02 (MK348510.1) with
coverage of 90%, 90%, 85%, and 71% and sequence identity
of 97.18%, 97.18%, 97.59%, and 96.87%, respectively, and
also with chromosomes of different S. aureus strains, such
as 2395 USA500 (CP007499.1) and AR_0468 (CP029657.1)
with coverage of 94% and 88%, and sequence identity of
99.22% and 99.19%, respectively. Besides the previously
mentioned four siphophages, the genome shows homology
(on different levels) with phages classified as members of
the Triavirus genus, such as Staphylococcus virus IPLA35
(EU861005.1), phiSLT (AB045978.2), phi12 (AF424782.1),
3a (AY954956.1), 42e (AY954955.1), and 47 (AY954957.1).
This is consistent with the morphological properties and
consolidates that the R4 phage belongs to the Triavirus genus
in the Siphoviridae family.
Figure 2 shows the phylogenomic relations of the R4
phage with other Staphylococcal phages and reveals the clos-
est relation to phage SAP8, SAP11, and SMSAP5.
Annotation resulted in 69 and 70 protein-coding
sequences by RAST and GeneMarkS, respectively (Figure 3).
Functions of certain genes were predicted accordingly by all
platforms. The genome is showing the modularity, character-
istic for Staphylococcal Siphoviridae, having six functional
modules: DNA packaging, head structure, tail structure, lysis,
lysogeny, and DNA replication/metabolism. Although genes
accountable for integration are present, no remnants of mobile
genetic elements and traces of truncated genes were observed.
3.4. Molecular Properties of the R4 Phage Endolysin, R4lys.
The genome of R4 contains a lysis cassette, consisting of a
lysin and a holin (Figure 3, yellow arrows, gene 26 and 27).
The 1455 bp long orf27 (from nucleotide 22 176 to 23 630)
coding for the 484 amino acid long R4lys endolysin shows
strong similarity (>96%) with the corresponding gene seg-
ment of Staphylococcus siphophages YMC/09/04/R1988
(KF598856.1), phi12 (AF424782.1), 47 (AY954957.1), LH1
(JX174275.1) of the Triavirus genus, siphophages 96
(AY954960.1), TEM123 (JQ779024.1) and TEM126
(HQ127381.1) of Phietavirus genus, and many other Staphy-
lococcus siphophages, each coding a muralytic peptide. The
endolysin of R4 phage itself was predicted to be an N-acetyl-
muramoyl-L-alanine amidase with two putative conserved
domains: an amidase-3 (pfam01520) in the middle (aa resi-
dues 181-362), and a SH3b (cell wall binding) domain at
the C-terminal (aa residues 402-470). Therefore, the coding
gene, orf27, was selected for amplification and cloning
(Figure 3) and for expression of the R4lys endolysin of R4
phage.
3.5. Protein Expression and Amidase Activity of R4lys. SDS-
PAGE analysis revealed the successful overexpression of
R4lys endolysin (Figure 4). Sole enhancement of a particular
band below 60 kDa only in lanes with orf27-pRSET A plas-
mid construct-containing BL21 lysates suggests the presence
of the overexpressed, target protein. In a time-course experi-
ment, it was observed that IPTG boosts the expression as
time passes (data not shown). However, overall results
showed that protein expression was observable even without
IPTG addition, and there is no remarkable difference
between expression levels of ON IPTG-treated and untreated
samples.
After purification of the R4lys, strong bands appeared
on the gel exclusively close to the 60 kDa protein ladder
band, also indicating the presence of the target protein.
The R4lys was not traceable with SDS-PAGE analysis from
the supernatant of the centrifuged ON cultures before cell
lysis, even by different protein precipitation methods (data
not shown). It seems that the protein is detained in inclu-
sion bodies of BL21 cells and not transported to the exter-
nal environment.
A difference was not visible between boiled and soni-
cated samples, regarding band intensity on the protein
gel. However, boiling abolished the enzymatic activity; thus,
no clearing zones could be observed on the zymogram gel
(Figure 4). In contrast, in the absence of heat treatment,
clearing zones in the gel were clearly observed due to the
lysis of the target bacterium. Other proteins in the protein
ladder or in the sonicated BL21 did not create clearing
zones, and by this, the amidase enzyme activity of R4lys
was confirmed.
100 nm
Figure 1: Transmission electron microscopic picture of phage R4




In this study, we have successfully isolated and character-
ized a novel Staphylococcus phage, R4, a new member of
the Triavirus genus in Siphoviridae. We have cloned and
expressed the R4lys amidase of the phage and showed that
the protein possesses lytic activity against the peptidoglycan
of the investigated host strain. With a functional assay, we
have identified the amidase gene that encoded the enzymat-
ically active enzyme and that can cause the lysis of the tar-
get cells.
According to a proposed classification, Staphylococcal
phages fall into three distinctive categories, determined by
their genome size. Class I phages with the smallest genome
(<20 kb) are podoviruses, class II with average genome size
(~40 kb) are siphoviruses, and class III is for myoviruses with
the largest genome (>125 kb) [20, 52, 53]. The 45 kb genome
size and the morphological properties of R4 phage suggest
that it belongs to class II of Staphylococcal phages. This is
confirmed by the modular structure of the R4 genome
(Figure 3), which is also a phenomenon, specific for this class
[53]. While Staphylococcal phages of the Myoviridae family
usually have a broad host range and lytic properties, making
them the best candidates for phage therapy purposes [33, 53–
56], siphoviruses are often temperate as they harbor a lysog-
eny module (Figure 3, purple). This implicates concerns of
their use as therapeutic agents, due to the integration into
the host genome as a prophage without causing lysis and to
potential horizontal gene transfer between bacterial genomes.
Remarkably, certain S. aureus virulence factors are encoded
by Staphylococcal prophages [20, 52, 53, 57]. Despite this
fact, it is experimentally proven that Staphylococcal temper-
ate siphoviruses can also be effective as antimicrobials against
MRSA in mouse models [23, 24], with a mutated lysogeny
module [58, 59]. Spot tests and TEM images (Figure 1) con-
firmed that R4 is indeed a lytic phage.
By focusing on the application of phage-derived lytic pro-
teins, we can exclude the concerns with phage therapy in gen-
eral. Besides resistance, for example, even obligatory lytic
phages have many proteins with hypothetical or unknown
function. Properties (structure, pharmacokinetics, etc.) of a
recombinant endolysin can be well-defined and better con-
trolled during the production of an antibacterial agent, in
terms of manufacturing a pure agent with detailed, uniform
composition [60].
Modularity is prevalent in Staphylococcal lysins, usually
consisting of 2 enzymatically active (amidase and CHAP)
and a cell wall binding SH3 conserved domain [21, 35, 36,
61]. The recently published LysSAP8 endolysin of SAP8
phage followed this trait [62] and showed promising proper-
ties for use as an antibacterial agent. Our results revealed that
the novel R4 phage and its R4lys endolysin are closely related
to SAP8 and LysSAP8, respectively. Homology search results
did not show a CHAP domain to be highly similar with the
same conserved segment of homologous proteins on the N′





















































Figure 2: Phylogeny tree of R4 phage. Genome-BLAST Distance Phylogeny (GBDP) tree inferred using the formula D0 and yielding average
support of 2%. The numbers above branches are GBDP pseudobootstrap support values from 100 replications. The branch lengths of the
resulting VICTOR trees are scaled in terms of the respective distance formula used. The OPTSIL clustering yielded twenty species clusters,
one cluster at the genus level, and one at the family level. Accession numbers are indicated next to the phage names. R4 phage is marked
with a black asterisk.
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with 2 of the conserved domains. Combining different lysins
with different cleavage sites and applying them at the same
time often results in synergy [21]. Synergistic activity can
be also achieved by using a lysin with certain antibiotics. This
can be further enhanced by creating chimeric fusion proteins
[61] by combining different domains with different cell wall
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Figure 3: Genome organization of the R4 phage. The 45 kb double-stranded DNA (black parallel lines) contains 69 coding genes, each
represented by arrows, annotated as indicated. The modular genome organization, characteristic for Staphylococcal siphophages is
highlighted by colors, indicating the coding regions belonging to one of the six functional modules. The 1455 bp long gene orf27, coding
for the endolysin (amidase), marked by a black asterisk, was cloned into the 2.9 kb pRSET A vector. The rightmost black image represents
the result of XhoI-HindIII probe digestion of orf27-pRSET A construct (lane “A”) and pRSET A control (lane “B”) on 1% agarose gel.
Excised 1.5 kb orf27 band is marked by a white asterisk. (Lane “L”: DNA ladder.)
Protein 




Figure 4: Visualization of the expressed recombinant R4lys endolysin. Comparison of sonicated and boiled crude expression cell lysates and
purified amidase by SDS-PAGE (left) and by zymogram (right) analysis. The letters are indicating that the same samples were added to both
gels in the corresponding lanes. Expressing BL21 cells were harboring the orf27-pRSET A plasmid. (a) Sonicated crude BL21 cells, boiled, with
5x sample buffer. (b) Column purified endolysin, boiled, with 5x sample buffer. (c) Sonicated crude BL21 cells, not boiled, with 5x sample
buffer. (d) Column purified endolysin, not boiled, with 5x sample buffer. (e) Column purified endolysin, not boiled, without 5x sample
buffer. SDS-PAGE revealed the presence of a protein, slightly below 60 kDa (black arrow is showing 60 kDa on the protein ladder),
regardless of the sample preparation method. In spite of the R4lys protein’s presence, zymography only showed its cell wall destroying
amidase activity when the sample was not boiled (white bands in lanes (c, d, e)).
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recognition specificities. Our results could contribute to the
development of these techniques.
5. Conclusions
Our results suggest that the R4 phage and its endolysin,
R4lys, can be promising candidates for further investigation
in phage-research.
As this phage targeted a high-risk international clone, our
results may aid the development of bacteriophage-based
therapeutic strategies for MRSA and/or VRSA strains, target-
ing major clonal lineages.
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